Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | PRKCG | P05129 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24216054 | 0.74 | HDAC6 (0.67) | CYP19A1KDR | |
| SCHEMBL29398947 | 0.74 | HDAC6 (0.67) | CYP19A1KDR | |
| SCHEMBL22557657 | 0.73 | CYP19A1 (0.68) | CYP19A1KDREPHB4TEKNPC1 | |
| SCHEMBL15425744 | 0.73 | CYP19A1 (0.64) | CYP19A1KDREPHB4TEKNPC1 | |
| SCHEMBL27926367 | 0.68 | NR1H2 (0.42) | NPC1RAB9AMAPK1MEN1KMT2A | |
| SCHEMBL15836586 | 0.68 | CYP19A1 (0.93) | CYP19A1KDREPHB4TEKNPC1 | |
| SCHEMBL935182 | 0.68 | CYP19A1 (1.00) | CYP19A1KDREPHB4TEKNPC1 | |
| SCHEMBL6505461 | 0.67 | NR1H2 (0.41) | NPC1RAB9AGSK3BMAPK13FGFR1 | |
| SCHEMBL4950 | 0.67 | NR1H2 (0.43) | NPC1RAB9AMAPK1MEN1KMT2A | |
| SCHEMBL2317632 | 0.66 | NPC1 (0.53) | NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269739-B | 1,3, 4-Diazole derivatives as histone deacetylase inhibitors | 奎马特里克斯公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-3956324-B1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX S L (ES) | 2024-02-21 | — | — | EP | disclosed |
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | FUNDACIÓN KERTOR (ES) | 2022-07-07 | — | — | US | disclosed |
| CN-114269739-A | 1,3,4- Oxadiazole derivatives as histone deacetylase inhibitors | 奎马特里克斯公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3956324-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212479-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212479-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC6, HDAC1, HDAC3 | CYP19A1 2858/4885KDR 4138/4885EPHB4 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.